Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 7/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | METTL3 | Q86U44 | 7/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14305600 | 0.85 | ADK (0.60) | ADKMETTL3 | |
| SCHEMBL13952411 | 0.85 | ADK (0.60) | ADKMETTL3 | |
| SCHEMBL13952395 | 0.85 | HIF1A (0.51) | ADKTP53STAT6HIF1APRMT5 | |
| SCHEMBL13603560 | 0.83 | SLC29A1 (0.43) | ADKTP53STAT6HIF1APRMT5 | |
| SCHEMBL20917266 | 0.81 | ADK (0.51) | ADKMETTL3PRMT5 | |
| SCHEMBL13184450 | 0.79 | SLC29A1 (0.50) | — | |
| SCHEMBL20058772 | 0.76 | ADK (0.61) | ADKPRMT5 | |
| SCHEMBL10268710 | 0.76 | ADK (0.61) | ADKPRMT5 | |
| SCHEMBL13603995 | 0.74 | PRMT5 (0.38) | ADKHIF1APRMT5WDR77 | |
| SCHEMBL14313964 | 0.74 | ADK (0.47) | ADKMETTL3PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036399-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036399-A1 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | HAVCR2, PNP, NSUN2 | ADK 298/4885TP53 2260/4885STAT6 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.